The EMCDDA–Europol Joint Report on new psychoactive substance (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and Europol concluded that sufficient information had been accumulated to merit the production of a Joint Report on MDPV as stipulated by Article 5.1 of the Decision.
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the ‘Decision’) stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by a majority of its members, consider that the information provided by the Member
State on a new psychoactive substance merits the collection of further information, this information shall be collated and presented by Europol and the EMCDDA in the form of a Joint Report (hereinafter the ‘Joint Report’).’ The Joint Report shall be
submitted to the Council, the European Medicines Agency (EMA) and the Commission. At the end of September 2013, the EMCDDA and Europol examined the available information on a new psychoactive substance 3,4-methylenedioxypyrovalerone, commonly known by the abbreviation ‘MDPV’, through a joint assessment based
upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information collected on MDPV satisfied criteria 1, 2, 3, 4 and 6. The two organisations therefore concluded that sufficient information had been accumulated to merit the production of a Joint Report on MDPV as stipulated by Article 5.1 of the Decision.